Oscar Health (OSCR) Expected to Announce Earnings on Wednesday

Oscar Health (NYSE:OSCR) is expected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $2.47 billion for the quarter. Oscar Health has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Oscar Health (NYSE:OSCR) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). The company had revenue of $2.42 billion during the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. Oscar Health’s revenue for the quarter was up 68.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS. On average, analysts expect Oscar Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Oscar Health Price Performance

OSCR opened at $16.72 on Tuesday. The company has a 50-day moving average of $15.22 and a 200-day moving average of $16.85. The company has a market capitalization of $4.13 billion, a P/E ratio of -278.55, a PEG ratio of 0.67 and a beta of 1.73. Oscar Health has a 1-year low of $12.84 and a 1-year high of $23.79. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on OSCR shares. Jefferies Financial Group started coverage on shares of Oscar Health in a research report on Tuesday, December 10th. They issued an “underperform” rating and a $12.00 target price for the company. Bank of America downgraded shares of Oscar Health from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $21.00 to $13.50 in a research report on Wednesday, November 6th. Finally, UBS Group assumed coverage on shares of Oscar Health in a research report on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price for the company. Two analysts have rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $21.56.

Insider Activity at Oscar Health

In other Oscar Health news, insider Mario Schlosser sold 6,516 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $18.08, for a total transaction of $117,809.28. Following the completion of the transaction, the insider now directly owns 81,962 shares of the company’s stock, valued at $1,481,872.96. The trade was a 7.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Thrive Partners Vii Growth Gp, bought 420,819 shares of Oscar Health stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $13.68 per share, with a total value of $5,756,803.92. Following the completion of the purchase, the director now directly owns 5,452,081 shares in the company, valued at $74,584,468.08. This trade represents a 8.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 1,055,478 shares of company stock valued at $14,432,852 and sold 103,610 shares valued at $1,847,519. Insiders own 25.11% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.